logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11633382 B1

PDFFull Text
Date of Patent:
Apr. 25, 2023

Filed:

Nov. 10, 2016

Treatment of er-negative breast cancer with an pdgf-cc inhibitor and anti-estrogen

Applicant:

Paracrine Therapeutics Ab, Bålsta, SE;

Inventors:

Ulf Eriksson, Bålsta, SE;

Kristian Pietras, Vellinge, SE;

Pernilla Roswall, Enköping, SE;

Assignee:

Paracrine Therapeutics AB, Balsta, SE;

Attorneys:

Dinsmore & Shohl LLP

Weston R. Gould

Primary Examiner:

Julie Wu

Assistant Examiner:

Sung Min Yoon

Int. Cl.
CPC ...
A61K 31/4196 (2006.01); A61P 35/00 (2006.01); A61K 31/138 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61K 31/40 (2006.01); A61K 31/4025 (2006.01); A61K 31/437 (2006.01); A61K 31/451 (2006.01); A61K 31/452 (2006.01); A61K 31/4535 (2006.01); A61K 31/506 (2006.01); A61K 31/565 (2006.01); A61K 31/566 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4196 (2013.01); A61K 31/138 (2013.01); A61K 31/40 (2013.01); A61K 31/4025 (2013.01); A61K 31/437 (2013.01); A61K 31/451 (2013.01); A61K 31/452 (2013.01); A61K 31/4535 (2013.01); A61K 31/506 (2013.01); A61K 31/565 (2013.01); A61K 31/566 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01);
Abstract

The invention discloses that ER-negative breast cancers can be converted into ER positive breast cancers, such as to a breast cancer of luminal-like phenotype by treatment with anti-PDGF-CC antibodies. ER-positive breast cancers, including luminal-like breast cancers can be treated with anti-estrogen treatment. On this basis the invention discloses that surprisingly, ER-negative breast cancers can be treated with anti-estrogen treatment, if the treatment is combined with treatment with anti-PDGF-CC antibodies. Said treatment may for example be an adjuvant treatment, for example a treatment aiming at reducing the risk of relapse of a breast cancer after removal of the primary tumor by surgery.

Find Patent Forward Citations

Loading…